Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: A review of the literature

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 751-766

  Weiner, Jennifer R ^a   Toy, Edmond L ^b   Sacco, Patricia ^c   Duh, Mei Sheng ^a  

^a ANALYSIS GROUP   (United States)

^b Analysis Group Inc   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adherence; Antibiotic; Compliance; Cost; Cystic fibrosis; Pseudomonas aeruginosa; Quality of life

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DEOXYRIBONUCLEASE; PANCREAS ENZYME; PLACEBO; RECOMBINANT ENZYME; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; GEOGRAPHIC DISTRIBUTION; HEALTH ECONOMICS; HOME CARE; HOSPITAL CARE; HUMAN; MEDICAL LITERATURE; MEDLINE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; ECONOMICS; HEALTH CARE COST; HOSPITALIZATION;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; HEALTH CARE COSTS; HUMANS; PATIENT COMPLIANCE; QUALITY OF LIFE; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; TOBRAMYCIN;

EID: 41949115920     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.751     Document Type: Review

References (66)

1. Cystic Fibrosis Foundation. Patient Registry 2005 Annual Report. Bethesda, MD: Cystic Fibrosis Foundation. Available from: http://www.cff.org/ UploadedFiles/research/ClinicalResearch/ PatientRegistryReport/2005%20 Patient%20Registry%20Report.pdf [Last accessed 28 June 2007]
2. National Institutes of Health. Office of Rare Diseases. Biennial and Annual Report on the Rare Diseases Research Activities at the National Institutes of Health FY 2004. Available from: http://rarediseases.info.nih.gov/html/reports/fy2004/summary04.html [Last accessed 28 June 2007]
3. Turcios NL. Cystic fibrosis: an overview. J Clin Gastroenterol 2005;39(4):307-17
4. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004;125(Suppl):1S-39S
5. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-56
6. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007;19(1):83-8
7. Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003;63(22):2501-20
8. Sexauer WP, Fiel SP. Aerosolized antibiotics in cystic fibrosis. Semin Respirat Crit Care Med 2003;24(6):717-26
9. Tramper-Stranders GA, Wolfs TF, Fleer A, et al. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007;26(1):8-12
10. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67(3):351-68
11. Hagerman JK, Knechtel SA, Klesper ME. Tobramycin solution for inhalation in cystic fibrosis patients; a review of the literature. Expert Opin Pharmacother 2007;8(4):267-425
12. Cystic Fibrosis Foundation. Drug Development Pipeline. Available from: http://www.cff.org/treatments/Pipeline/ [Last accessed 26 June 2007]
13. Krauth C, Jalilvand N, Welte T, Busse R. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003;21(14):1001-24
14. Lelorier J, Perreault S, Birnbaum H, et al. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clin Ther 2000;22(1):140-51
15. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
16. Iles R, Legh-Smith J, Drummond M, et al. Economic evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cyst Fibros 2003;2(3):120-8
17. Taccetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Resiprat J 2005;26:458-61
18. Wolter JM, Bowler SD, Nolan PJ, et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respirat J 1997;10(4):896-900
19. Elliott RA, Thornton J, Webb AK, et al. Comparing costs of home- versus hospital-based treatment of infections in adults in a specialist cystic fibrosis center. Int J Technol Assess Health Care 2005;21(4):506-10
20. Thornton J, Elliott RA, Tully MP, et al. Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. J Cyst Fibros 2005;4(4):239-47
21. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997;24(1):42-7
22. Baumann U, Stocklossa C, Greiner W, et al. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003;2(2):84-90
23. Schreyogg J, Hollmeyer H, Bluemel M, et al. Hospitalisation costs of cystic fibrosis. Pharmacoeconomics 2006;24(10):999-1009
24. Horvais V, Touzet S, Francois S, et al. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Int J Technol Assess Health Care 2006;22(4):525-31
25. Johnson JA, Connolly MA, Jacobs P, et al. Cost of care for individuals with cystic fibrosis: a regression approach to determining the impact of recombinant human DNase. Pharmacotherapy 1999;19(10):1159-66
26. Lieu TA, Ray GT, Farmer G, Shay GF. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103(6):e72
27. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992;47(9):684-9
28. Littlewood JM, Cross E. Present day treatment of cystic fibrosis: its content and cost. In: Clinical Economics in Gastroenterology. Bodger K, Daly M, Heatley RV, editors. Oxford: Blackwell Science; 2000
29. Wildhagen MF, Verheij JB, Hilderink HB, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1. Thorax 1996;51(3):298-301
30. Wildhagen MF, Verheij JB, Verzijl JG, et al. The non-hospital costs of care of patients with CF in The Netherlands: results of a questionnaire. Eur Respirat J 1996;9(11):2215-9
31. Tullis DE, Guyatt GH. Quality of life in cystic fibrosis. Pharmacoeconomics 1995;8:23-33
32. Quittner AL. Measurement of quality of life in cystic fibrosis. Curr Opin Pulmon Med 1998;4(6):326-31
33. Abbot J, Hart A. Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review. Health Qual Life Outcomes 2005;24(3):19
34. Quittner AL, Buu A, Messer MA, et al. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128(4):2347-54
35. Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol 2003;28(8):535-45
36. Gee L. Abbott J, Conway SP, et al. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54
37. Abbott J, Gee L. Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design. Pediatr. Drugs 2003;5(1):1-56
38. Congleton J, Hodson ME, Duncan-Skingle F. Quality of life in adults with cystic fibrosis. Thorax 1996;51(9):936-40
39. Johnson JA, Connolly M, Zuberbuhler P, Brown NE. Health-related quality of life for adults with cystic fibrosis: a regression approach to assessing the impact of recombinant human DNase. Pharmacotherapy 2000;20(10):1167-74
40. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121(1):64-72
41. Poespodihardjo R, Tamm M, Mordasini C, et al. Quality of life and psychological distress in adults with cystic fibrosis (CF). American Thoracic Society International Conference; 2005
42. Shepherd SL, Hovell MF, Harwood IR, et al. A comparative study of the psychosocial assets of adults with cystic fibrosis and their healthy peers. Chest 1990;97(6):1310-6
43. Shepherd SL, Hovell MF, Slymen DJ, et al. Functional status as an overall measure of health in adults with cystic fibrosis: further validation of a generic health measure. J Clin Epidemiol 1992;45(2):117-25
44. De Jong W, Kaptein AA, Van Der Schans CP, et al. Quality of life in patients with cystic fibrosis. Pediatr Pulmonol 1997;23(2):95-100
45. Wahl AK, Rustoen T, Hanestad BR, et al. Living with cystic fibrosis: impact an global quality of life. Heart Lung 2005;34(5):324-31
46. Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002;33(4):269-76
47. Hill DM, Fukushima LK, Hsu E, Woo MS. Obstacles to use of high-dose aerosolized tobramycin in eligible cystic fibrosis patients. American Thoracic Society International Conference; 2005
48. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360(9338):978-84
49. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57(3):212-6
50. Ramstrom H, Erwander I, Mared L, et al. Pharmaceutical intervention in the care of cystic fibrosis patients. J Clin Pharm Ther 2000;25(6):427-34
51. Esmond G, Butler M, McCormack AM. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. J Clin Nurs 2006;15(1):52-60
52. Yi MS, Tsevat J, Wilmott RW, et al. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? J Pediatr 2004;144(6):711-8
53. Orenstein DM, Pattishall EN, Nixon PA, et al. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990;98(5):1081-4
54. Munzenberger PJ, Van Wagnen CA, Abdulhamid I, Walker PC. Quality of life as a treatment outcome in patients with cystic fibrosis. Pharmacotherapy 1999;19(4):393-8
55. Bradley J, McAlister O, Elborn S. Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis. Eur Respirat J 2001;17:712-5
56. Kupferberg DH, Morgan CG, Brown AL, Conrad DJ. Quality of life measures sensitive to change in exacerbation of cystic fibrosis. American Thoracic Society International Conference; 2003
57. Modi AC, Lim C, Driscoll KA, et al. Intravenous antibiotic treatment of a pulmonary exacerbation: effects an child and adolescent health-related quality of life. Pediatr Pulmonol 2007;42(S30):202-412
58. Kettler LJ, Sawyer SM, Winefield HR, Greville HW. Determinants of adherence in adults with cystic fibrosis. Thorax 2002;57(5):459-64
59. Dodd ME, Webb AK. Understanding non-compliance with treatment in adults with cystic fibrosis. J R Soc Med 2000;93(Suppl 38):2-8
60. Pendleton DA, David TJ. The compliance conundrum in cystic fibrosis. J R Soc Med 2000;93(Suppl 38):9-13
61. Smith BA, Wood BL. Psychological factors affecting disease activity in children and adolescents with cystic fibrosis: medical adherence as a mediator. Curr Opin Pediatr 2007;19(5):553-8
62. Velasco MV, Zaldua I, Gonzalez A, et al. Inhaled antibiotic treatment adherence in cystic fibrosis. American Thoracic Society International Conference; 2002
63. Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006;5(3):177-85
64. Modi AC, Quittner AL. Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 2006;31(8):846-58
65. Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax 1996;51:29-33
66. Delambo KE, Ievers-Landis CE, Drotar D, Quittner AL. Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. J Pediatr Psychol 2004;29(5):343-53